Patient Information

We believe we can offer patients improved therapies to more effectively treat debilitating conditions or diseases. We focus our drug discovery efforts on medical conditions where we believe current drugs are not providing optimal therapeutic benefit.

Our most advanced product candidate, XP13512 (which is also known as Solzira™ in the U.S. market), is a new chemical structure that was developed by XenoPort. We and GSK, one of our partners for the development and commercialization of XP13512, are evaluating Solzira in the United States to treat restless legs syndrome, or RLS, and certain forms of neuropathic pain.

XP13512 was shown to be safe and well tolerated in Phase 1 clinical trials. We have successfully completed two Phase 2 and three Phase 3 efficacy trials in RLS patients. We believe these trials could support an NDA filing and potential market approval of XP13512 for the treatment of RLS.

We also believe that XP13512 may offer benefits over current treatments for neuropathic pain. We have conducted a successful Phase 2a clinical trial of XP13512 as a potential treatment of post-herpetic neuralgia, a type of neuropathic pain. GSK is conducting neuropathic pains trials in its territory, and Astellas, our other partner for XP13512, is conducting Phase 2 painful diabetic neuropathy and RLS trials in Japan.

Our second product candidate, XP19986, is also a new chemical structure that was developed by XenoPort. We have evaluated XP19986 in a Phase 2a clinical trial as a potential treatment for gastroesopheal reflux disease, or GERD. We are currently evaluating it in separate Phase 2 GERD and spasticity clinicl trials.

---

This icon indicates a link to an external site.